Single-cell RNA sequencing: a new frontier in prostate cancer research
Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men worldwide. Despite decades of research, many aspects of this complex disease, including its mechanisms of initiation, progression, and resistance to therapy, remain incompletely understood. Recently, revolutionary advances in single-cell RNA sequencing (scRNA-seq) technologies have transformed the landscape of prostate cancer research, enabling unprecedented exploration of the cellular heterogeneity within tumors and their microenvironmental context. These insights are catalyzing a paradigm shift in our comprehension of prostate biology from development through malignancy, and hold promise for radically improved diagnostic and therapeutic approaches.
At its core, single-cell RNA sequencing provides the ability to profile gene expression at the resolution of individual cells, overcoming the limitations inherent in traditional bulk sequencing approaches that average signals across millions of heterogeneous cells. This granular perspective uncovers the complex mosaic of distinct cell populations within the prostate, including epithelial, stromal, and immune subtypes, each with unique transcriptomic signatures and functional roles. By charting this cellular diversity, researchers can trace the evolutionary trajectories of tumor clones, identify rare subpopulations driving disease, and understand dynamic cellular responses to stimuli such as androgen deprivation therapy.
One of the most striking revelations enabled by scRNA-seq in prostate cancer is the extent of cellular lineage plasticity, a phenomenon whereby tumor cells can shift identity and phenotype in response to environmental and therapeutic pressures. This plasticity underpins resistance mechanisms to conventional androgen receptor (AR)-targeted therapies that are the mainstay treatment for advanced disease. Through single-cell profiling, distinct states of AR dependence and independence have been mapped, uncovering transitional populations that evade therapy by adopting neuroendocrine or stem-like characteristics. These findings could inform novel therapeutic strategies aimed at intercepting or reversing such lineage switches.
Equally consequential is the elucidation of the tumor microenvironment (TME), a complex consortium of support cells including fibroblasts, endothelial cells, and diverse immune infiltrates that orchestrate tumor progression and immune evasion. scRNA-seq has unveiled remarkable heterogeneity within stromal and immune compartments, revealing subtypes that either promote or restrain tumor growth. For example, distinct populations of tumor-associated macrophages and T cells have been identified with varying roles in immunomodulation, suggesting new avenues for immunotherapy by selectively targeting pro-tumorigenic microenvironment components.
Complementing scRNA-seq, emerging spatial transcriptomics technologies now enable the localization of gene expression patterns within the intact tissue architecture. This innovation adds a critical layer of spatial context to single-cell data, preserving information on how cells are organized and interact within tumor niches. In prostate cancer, spatial mapping has been pivotal in deciphering the architecture of tumor ecosystems, revealing gradients of cellular states, spatially restricted gene expression programs, and niches enriched for therapy-resistant populations. Together, these technologies synergize to provide a multidimensional view of tumor biology with vast implications for precision medicine.
A key capability of these integrated approaches is the bioinformatic inference of large-scale genomic alterations, including copy number variants (CNVs), directly from transcriptomic data. This innovation bypasses the need for separate DNA sequencing, enabling simultaneous analysis of genomic and transcriptomic heterogeneity at single-cell resolution. In prostate cancer, this integrated genomic–transcriptomic profiling illuminates the clonal evolution of tumor cells, revealing patterns of genetic instability and their transcriptomic consequences that drive aggressive behavior and therapeutic resistance. Such insights are vital for understanding the evolutionary dynamics underpinning metastasis and relapse.
Beyond deepening biological understanding, single-cell and spatial transcriptomics offer tangible clinical potential. By resolving the cellular and molecular heterogeneity that underlies varied patient outcomes, these technologies pave the way for sub-stratification of prostate cancer patients into molecularly defined subgroups. This stratification could enhance prognostication, inform therapeutic choice, and reduce overtreatment. Furthermore, identification of novel biomarkers expressed in distinct cell populations or niches can fuel the development of more sensitive and specific diagnostic assays.
Therapeutically, the knowledge gained through scRNA-seq enables the rational design of interventions tailored to tumor subtypes and their microenvironments. For instance, targeting stromal cells that support tumorigenesis or modulating immune subsets to reverse immunosuppression could augment existing treatments. In addition, therapeutics that specifically disrupt lineage plasticity mechanisms might overcome resistance to androgen deprivation therapy, addressing a major clinical challenge in advanced prostate cancer management.
Importantly, the technological and computational sophistication required to perform and interpret single-cell and spatial transcriptomic data is rapidly maturing. Advances in sequencing platforms, microfluidics, and imaging techniques, combined with innovative algorithms for data integration and visualization, are fostering wider accessibility and scalability of these powerful tools. This democratization is accelerating discoveries in prostate cancer biology and expanding possibilities across oncology and beyond.
Nevertheless, significant challenges remain. Integrating multimodal datasets, including transcriptomic, proteomic, epigenetic, and genomic information, at single-cell resolution remains computationally intensive and technically demanding. Moreover, standardization of protocols and analytical pipelines is necessary to ensure reproducibility and comparability across studies. Addressing tumor heterogeneity in diverse patient populations and disease contexts also requires extensive sampling and longitudinal analyses.
Looking ahead, the convergence of single-cell and spatial transcriptomics with other emerging modalities such as single-cell ATAC-seq, proteogenomics, and high-throughput imaging promises to fully characterize the prostate tumor ecosystem across multiple dimensions. Coupling these data with clinical parameters and treatment responses through integrative artificial intelligence approaches could unlock predictive models for personalized therapy. Ultimately, these advances will transform prostate cancer from an enigmatic and heterogeneous disease into one that can be precisely dissected, monitored, and conquered.
The journey from organogenesis to metastatic prostate cancer is being rewritten through the lens of single-cell biology. As researchers continue to unravel the intricate interplay of epithelial, stromal, and immune networks within the prostate, new vulnerabilities emerge to challenge the resilience of cancer. These insights herald a new age of precision oncology where therapy is tailored not only to the genetic makeup of the tumor but also to its cellular architecture, evolutionary trajectory, and microenvironmental crosstalk. The promise of single-cell and spatial RNA sequencing for prostate cancer is immense—offering hope for improved outcomes and survival for millions of men worldwide.
Subject of Research: Prostate cancer biology and tumor microenvironment characterization through single-cell and spatial transcriptomics.
Article Title: Single-cell and spatial RNA sequencing in prostate cancer
Article References:
Ali, A., Mikutenaite, M., Weischenfeldt, J. et al. Single-cell and spatial RNA sequencing in prostate cancer. Nat Rev Urol (2026). https://doi.org/10.1038/s41585-026-01149-4
Image Credits: AI Generated
